Did you know that there’s a connection between heart health and brain health?
It is now possible to be monitored by the Montreal Heart Institute’s specialists by taking part in the BRAIN-AF clinical study, a world first, which could decrease the rate of cognitive impairment in patients with atrial fibrillation.
In collaboration with the Canadian Stroke Prevention Intervention Network, the pharmaceutical company Bayer, and the Montreal Health Innovations Coordinating Center (MHICC), the MHI’s team of specialists and researchers along with multidisciplinary teams from about fifty Canadian centres want to demonstrate that taking a low dose of rivaroxaban, an anticoagulant, could decrease the risk of developing cognitive impairment in patients with atrial fibrillation by reducing the rate of cerebral microemboli.
"According to the World Health Organization (WHO), 47.5 million people worldwide have dementia.* In Canada, approximately 700,000 people currently have dementia, and this number is expected to triple by 2050. It would therefore be a major victory if we could prevent some cases of dementia, including those linked to atrial fibrillation, thanks to the BRAIN-AF study," says Dr. Léna Rivard, cardiologist and director of the study.
You whish to watch our French Virtual Conference? Click HERE
A virtual conference will be held in English shortly. Stay tuned for more details.
If you are a Canadian resident, you can take part in the study.
Contact a study representative at 1-844-535-2486.